I’d ditch ReNeuron Group plc to buy another Neil Woodford favourite

This profitable growth company could serve you better than gambling with ReNeuron Group plc (LON: RENE).

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

The share price of ReNeuron Group (LSE: RENE) continued its inexorable slide downwards this morning on release of the full-year results.

Financial results not pretty

The firm is a clinical-stage research company developing cell-based therapies. You have to scroll a long way down the results report — past descriptions of all the exciting research activities the firm is undertaking — before you get to the financial information.

When you get there, it’s not pretty. Revenues in the year were just £46k made up of royalties from non-therapeutic licensing activities. On top of that, the company received grant income of £0.85m. But that income is woefully short of what ReNeuron needs to keep its boffins employed with an honest income.

Passive income stocks: our picks

Do you like the idea of dividend income?

The prospect of investing in a company just once, then sitting back and watching as it potentially pays a dividend out over and over?

If you’re excited by the thought of regular passive income payments, as well as the potential for significant growth on your initial investment…

Then we think you’ll want to see this report inside Motley Fool Share Advisor — ‘5 Essential Stocks For Passive Income Seekers’.

What’s more, today we’re giving away one of these stock picks, absolutely free!

Get your free passive income stock pick

Escalating costs

Indeed, research and development costs increased to £16.65m from £10.27m the year before, and general and administrative expenses notched up a further £4.14m cost, up a tad from the previous year.

The bottom line is that ReNeuron increased its loss to £15.57m for the year, up from £11.35m the year before. One financial glimmer of light is that the firm still had around £53m in the bank on 31 March – and falling.

The company is notable in that the institution with the largest listed investment is Woodford Investment Management LLP. Neil Woodford and the other investors here must be hoping that ReNeuron can commercialise some of its creations before the cash runs out. If not, the firm will be back to the market for more money and the share price will continue its journey south.

Potential for spectacular outcomes

Of course, spectacular investing results can be achieved with new businesses like this. All we need is for ReNeuron to get one of its treatments through all the trial stages and it could be sitting on a hot property. Maybe a big pharmaceutical company will move in at that point and pay millions for the new product or even for the whole company, or ReNeuron could take the product to market on its own.

However, investing in ReNeuron now is a gamble because a lot could go wrong, such as how long the whole process may take, and whether an eventual finished product experiences the hoped-for demand from end users and clinicians.

Show me financial progress first

I would invest in an early-stage firm such as ReNeuron, but only after seeing evidence of an imminent change in financial fortunes, such as a major commercialisation announcement or evidence of revenues from trading and declining losses.

Instead of ReNeuron now, I’d rather invest in another Neil Woodford favourite, growing mid-cap specialist healthcare company BTG (LSE: BTG). The firm is making good progress with a number of medical treatments and has an impressive record growing its earnings each year. City analysts following the firm expect earnings per share to advance 28% for the current year to March 2018 and 15% next year.

Growth is very much still on the table and chief executive Louise Makin recently explained that double-digit product sales generating significant cash flows enable the firm to invest in product innovation, clinical data, geographic expansion and acquisition. It’s a virtuous self-funding circle that potentially leads to even more growth, and very different to the situation at ReNeuron where further funds may end up coming from investors before a commercial breakthrough happens.

British CEO gobbles up £238,000 of own stock

What company does he run?

And why is he so confident in its long-term potential?

This new report - ‘One Top Growth Stock from The Motley Fool’ - reveals the full details, both risks and opportunities. Some of which you may find frankly, unbelievable.

Though past performance does not guarantee future results, over the past 5 years, it’s seen consistent:

  • Double-digit revenue growth
  • Returns on capital almost 600% the UK average
  • Now, profits are exploding again - up 46% in 1 year!

It’s no wonder insiders are buying this stock hand over fist. Last year, they bought a total £492,000 of shares. And now might be the ideal moment to join them.

So please, don’t miss this report, ‘One Top Growth Stock from The Motley Fool’ Including both risks and opportunities.

Secure your FREE copy now

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Kevin Godbold has no position in any shares mentioned. The Motley Fool UK has recommended BTG. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Google office headquarters
Investing Articles

$1bn a day! This S&P 500 share still looks like a stock market bargain after Q1 earnings

The owner of Google and YouTube just announced strong results to the stock market, including another massive $70bn share buyback.

Read more »

BUY AND HOLD spelled in letters on top of a pile of books. Alongside is a piggy bank in glasses. Buy and hold is a popular long term stock and shares strategy.
Investing Articles

3 cheap FTSE 100 stocks with big dividends to consider buying right now

Sector weakness in some FTSE 100 industries has also left some of my long-term favourite stocks offering attractive dividend yields.

Read more »

Growth Shares

Forecast: £1,000 invested in Rolls-Royce shares could be worth this much by next year

Jon Smith talks through both his opinion and analysts’ forecasts when trying to predict where Rolls-Royce shares could head from…

Read more »

Man putting his card into an ATM machine while his son sits in a stroller beside him.
Investing Articles

£5,000 invested in Lloyds shares 5 years ago is now worth…

The price of Lloyds shares has more than doubled over the past five years. However, our writer’s cautious about the…

Read more »

Investing Articles

Up 58% in a year, the BT share price could be the FTSE 100 target to beat in 2025

The BT share price has been steadily climbing back since newish boss Allison Kirkby came on board. Is the new…

Read more »

Businessman hand stacking money coins with virtual percentage icons
Investing Articles

£10,000 invested in Nvidia stock 5 years ago is now worth…

Even after the Nvidia stock falls of the past couple of months, its five-year performance remains stunning. And it could…

Read more »

artificial intelligence investing algorithms
Investing Articles

I asked ChatGPT for the best UK stocks to buy for my portfolio in the market sell-off. Here’s what it said

When Edward Sheldon asked the generative AI app for the best stocks to buy amid the market pullback, he was…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

Could now be a rewarding moment to buy shares?

Christopher Ruane's looking for shares to buy in a turbulent market. But while he's focused on quality, he's equally interested…

Read more »